Core Insights - Warren Buffett's Berkshire Hathaway has increased its stake in Liberty Media Corp, acquiring over 1.3 million shares at prices ranging from $25.36 to $26.55, totaling more than $29.3 million, bringing its total holdings to approximately 69 million shares [4][6] - Insider buying activity has generally slowed, but notable purchases were made in various sectors, including media, biotechnology, and industrials [1][19] Liberty Media - Berkshire Hathaway has boosted its stake in Liberty Media Corp (NASDAQ: LSXMK) to around 69 million shares after a previous purchase of over $66 million [4] - The stock price of Liberty Media has decreased by about 15% since the beginning of the year, and the company is in the process of merging with Sirius XM Holdings Inc [4][6] Acrivon Therapeutics - Perceptive Advisors purchased over 2.3 million shares of Acrivon Therapeutics Inc (NASDAQ: ACRV) at $8.50 per share, totaling around $20 million [9] - The stock has risen over 114% since the start of the year, largely due to a $130 million funding announcement, with a mean price target suggesting an additional upside of approximately 84% [9] UL Solutions - Insiders, including CEO Jennifer Scanlon, bought more than 590,600 shares of UL Solutions Inc (NYSE: ULS) at $28.00 per share, costing over $16.5 million [12] - The shares were last seen trading around $34, indicating a positive post-IPO performance despite recent market fluctuations [12] OncoCyte - Broadway Partners and other insiders acquired nearly 2.5 million shares of OncoCyte Corp (NASDAQ: OCX) at prices between $2.91 and $2.95, totaling over $7.1 million [14] - The stock has declined almost 25% in the past 90 days, but remains above its 52-week low of $2.08, with a consensus price target of $3.90 [14] GrafTech International - Colonial House Capital purchased around 2.3 million shares of GrafTech International Ltd (NYSE: EAF) at $1.78 per share, costing about $4.1 million [17] - The stock has fallen more than 32% year-to-date, with a consensus price target of $1.75, indicating limited analyst support for buying shares [17] Other Notable Insider Buying - Recent insider purchases were reported at companies including AES, America's Car-Mart, Federal Agricultural Mortgage, Lovesac, Neogen, Rocket Companies, RXO, SAIC, Walgreens Boots Alliance, and WD-40 [19]

Core Insights - Acrivon Therapeutics is hosting a virtual corporate R&D event on April 24, 2024, to present updates on its precision oncology pipeline and engage in an interactive Q&A session [1][2] Company Overview - Acrivon Therapeutics is a clinical stage biopharmaceutical company focused on developing precision oncology medicines using its proprietary platform, Acrivon Predictive Precision Proteomics (AP3), which identifies patients whose tumors are likely to respond to specific treatments [3] - The AP3 platform measures compound-specific effects on tumor cell protein signaling networks and drug-induced resistance mechanisms, facilitating drug design optimization and the creation of proprietary OncoSignature companion diagnostics [3] Pipeline Developments - The lead candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for multiple tumor types [3] - ACR-368 has received Fast Track designation from the FDA for use as monotherapy in patients with platinum-resistant ovarian or endometrial cancer based on OncoSignature-predicted sensitivity [3] - The ACR-368 OncoSignature test, which is not yet approved, has been evaluated in preclinical studies, including two blinded, prospectively-designed studies involving tumor biopsies from previous trials [3] - The FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay to identify ovarian cancer patients who may benefit from ACR-368 treatment [3] - Acrivon is also developing ACR-2316, a potent WEE1/PKMYT1 inhibitor, and other preclinical programs leveraging the AP3 platform [3]

Group 1 - Acrivon Therapeutics announced a $130 million private placement to fund its product pipeline development [1] - The company sold 8,235,000 shares at $8.50 per share and pre-funded warrants for 7,060,000 shares at $8.49 each [1] - The funding will support the development of ACR-368, ACR-2316, and an undisclosed cell cycle regulatory program [2] Group 2 - ACRV stock surged by 54.9% with over 14 million shares traded, significantly above its average daily volume of about 73,000 shares [2] - The investment comes from notable healthcare and life sciences investors, including RA Capital Management and Perceptive Advisors [1]

WATERTOWN, Mass, April 09, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced that it has entered into a securities purchase a ...

akinbostanci There is a strong case to be made for having a position in small cap stocks at this time. Reasons include: Anticipated Fed easing may lift small caps more than large caps Mean reversion - small caps have underperformed large caps by historic amounts over the past five years A potential slow down or reversal of the rally in tech which has disproportionally benefitted large cap indices such as the S&P 500. Despite this, I recently wrote an article on Seeking Alpha recommending that investors s ...

Exhibit 99.1 Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights WATERTOWN, Massachusetts, March 28, 2024 – Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________________ TO ____________________ Commission File Number 001-41551 Acrivon Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) | D ...

Core Insights - Acrivon Therapeutics is advancing ACR-2316, a selective dual WEE1 and PKMYT1 inhibitor, demonstrating strong preclinical activity and designed for superior single-agent efficacy [1][2] - The company utilizes its proprietary AP3 platform to identify patient responders and mechanisms of drug resistance, enhancing the potential for effective cancer treatments [6] Group 1: Product Development - ACR-2316 is the first fully internally-discovered candidate from Acrivon, generated through co-crystallography-based drug design, aimed at addressing limitations of existing WEE1 and PKMYT1 inhibitors [2] - Acrivon is also advancing ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2 trial with Fast Track designation from the FDA for specific cancer types [6] Group 2: Research Presentation - Acrivon will present data at the AACR Annual Meeting from April 5-10, 2024, showcasing the potential of ACR-2316 and insights from the AP3 platform regarding resistance mechanisms to ACR-368 [1][3] - The presentations will include a poster on ACR-2316's design and efficacy, as well as findings on overcoming resistance to ACR-368 through combination treatments [3][4]

Core Insights - Acrivon Therapeutics is advancing ACR-2316, a selective dual WEE1 and PKMYT1 inhibitor, demonstrating strong preclinical activity and designed using the AP3 platform for enhanced single-agent efficacy [1][2] - The company will present data at the AACR Annual Meeting in April 2024, showcasing the broad applicability of its AP3 technology and its potential to address drug resistance mechanisms [2][3] Company Overview - Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, utilizing its proprietary AP3 platform to match treatments to patients based on tumor sensitivity [1][6] - The AP3 platform measures compound-specific effects on tumor cell protein signaling networks and drug resistance mechanisms, facilitating drug design optimization and patient identification for specific therapies [6] Pipeline and Development - Acrivon's lead candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2 trial with Fast Track designation from the FDA for platinum-resistant ovarian or endometrial cancer [6] - ACR-2316 is the first fully internally-discovered candidate from Acrivon, generated through co-crystallography-based drug design, aimed at overcoming limitations of existing WEE1 and PKMYT1 inhibitors [2][6] Upcoming Presentations - Acrivon will present two key datasets at the AACR Annual Meeting: one on ACR-2316's design and efficacy, and another on the mechanism of resistance to ACR-368 and a combination treatment strategy [3][6]

Core Insights - Acrivon Therapeutics has appointed Dr. Ivana Magovčević-Liebisch to its board of directors, bringing over 25 years of experience in global business and R&D operations [2][3] Company Overview - Acrivon Therapeutics is a clinical stage biopharmaceutical company focused on developing precision oncology medicines using its proprietary platform, Acrivon Predictive Precision Proteomics (AP3) [4] - The AP3 platform is designed to identify patients whose tumors are likely to respond to specific treatments by analyzing the tumor cell protein signaling network and drug resistance mechanisms [4] - Acrivon is advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for multiple tumor types [4] - ACR-368 has received Fast Track designation from the FDA for use as monotherapy in patients with platinum-resistant ovarian or endometrial cancer [4] - The ACR-368 OncoSignature test, which is still pending regulatory approval, has been evaluated in preclinical studies and has received Breakthrough Device designation from the FDA [4] Leadership Insights - Dr. Magovčević-Liebisch has a strong background in leading business development and commercialization efforts, having previously held executive roles at Vigil Neuroscience, Ipsen, and Teva Pharmaceutical Industries [2] - She has a Ph.D. in genetics from Harvard University and a J.D. in high technology law, indicating a robust academic foundation to support her role at Acrivon [2][3]